EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Invasive breast cancer in this analysis is defined as ICD-10 codes C50.0-50.9, while non-invasive DCIS breast cancer is defined as ICD-10 code D05.1; both types of breast cancer are based on country-specific, nationally representative sources. Uniform diagnostic criteria are used for all segmentations across the 8MM, where a breast biopsy was used to confirm cases of breast cancer. In addition, comparable staging criteria by the AJCC (American Joint Committee on Cancer) and UICC (Union for International Cancer Control) were applied across all 8MM.

GlobalData epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60-69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015. The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN.

GlobalData epidemiologists utilized comprehensive, country-specific data from national breast cancer registries and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident and five-year diagnosed prevalent cases of breast cancer. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident cases of breast cancer.

Scope

The Breast Cancer EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.

The breast cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.3.1US

2.3.25EU

2.3.3Japan

2.3.4China (Urban)

2.3.5Prevalence and Survival

2.4Forecast Methodology

2.4.1Sources Used Tables

2.4.2Forecast Assumptions and Methods

2.4.3Sources Not Used

2.5Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015–2025)

2.5.1Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer

2.5.2Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

2.6Epidemiological Forecast for Invasive Breast Cancer (2015–2025)

2.6.1Diagnosed Incident Cases of Invasive Breast Cancer

2.6.2Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer

2.6.3Age-Standardized Diagnosed Incidence of Invasive Breast Cancer

2.6.4Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer

2.6.5Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis

2.6.6Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status

2.6.7Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis

2.6.8Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression

2.6.9Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression

2.7Discussion

2.7.1Epidemiological Forecast Insight

2.7.2Limitations of the Analysis

2.7.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2About the Authors

3.2.1Epidemiologists

3.2.2Reviewers

3.2.3Global Director of Therapy Analysis and Epidemiology

3.3About GlobalData

3.4About EpiCast

3.5Disclaimer

Table

Table 1: Risk Factors and Comorbidities for Breast Cancer

Table 2: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)

Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer

Table 4: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status

Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status

Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression

Table 14: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer

Table 15: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 16: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Table 17: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 18: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015

Table 19: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015–2025

Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015

Table 21: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015

Figures

Figure 1: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2005?2014

Figure 2: Case Flow Map

Figure 3: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, Selected Years, 2015–2025

Figure 4: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 5: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, Selected Years, 2015–2025

Figure 6: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 7: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015

Figure 8: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, Select Years, 2015–2025

Figure 9: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015

Figure 11: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 12: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 13: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 14: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages =18 Years, 2015

Figure 15: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 16: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015

Figure 17: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages =18 Years, 2015

Figure 18: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015

Figure 19: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages =18 Years, 2015

Frequently asked questions

EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.